Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy

Figure 1 Study flowchart. Of 1152 patients with advanced pancreatic cancer, 1031 received first-line 5-fluorouracil/leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine plus albumin-bound paclitaxel, and 559 and 199 received second-line and third-line chemotherapy, respectively. 167 patients received best supportive care and their survival outcomes are known. In total, 141 patients were enrolled in this study. FOLFIRINOX: 5-fluorouracil/leucovorin, irinotecan, and oxaliplatin; GNP: Gemcitabine plus nab-paclitaxel; PD: Progressive disease.